The FDA has approved AbbVie's Juvmo (tavapadon), the first selective D1/D5 dopamine receptor agonist cleared for Parkinson's disease, dosed once daily as monotherapy in early disease or as an adjunct to levodopa. Phase 3 TEMPO data showed an increase of 1.7 hours in daily on time without troublesome dyskinesia versus 0.6 hours with placebo, alongside a 1.9-hour reduction in off time, with efficacy reported through 85 weeks. Receptor-subtype selectivity marks a shift away from the broad dopaminergic stimulation that has defined agonist therapy for decades.
Key Points
- First selective D1/D5 receptor agonist approved for Parkinson's disease
- On time without troublesome dyskinesia rose 1.7 hours versus 0.6
- Once-daily dosing; US availability expected October 2026
Longevity Analysis
Parkinson's disease shortens healthspan primarily through the erosion of movement, autonomy and daily function rather than through a single terminal event, which makes on time — hours of usable motor control — a more meaningful endpoint than symptom scores alone. Targeting D1/D5 receptors specifically, rather than saturating the broader dopamine system, reflects a wider move toward interventions precise enough to restore signaling without amplifying the side effects that limit adherence; nausea, dizziness, anxiety and hallucinations remain among the reported treatment-emergent events. For patients and clinicians, the practical value lies in a once-daily regimen that is realistic to sustain over years, since motor benefit in this condition depends entirely on uninterrupted dosing over long horizons.
Original published by Longevity.Technology.